Bayer

Last updated April 7, 2026

Innovation Areas

Sleep apnea pharmacotherapy: BayerRecent Research Landscape

Sleep apnea and related respiratory conditions lack effective pharmacological interventions, requiring specific combinations of ion channel blockers and receptor antagonists to achieve therapeutic efficacy.

What technical problems is Bayer addressing in Sleep apnea pharmacotherapy?

Adrenergic airway muscle dysfunction

(11)evidences

Sleep-related breathing disorders like obstructive sleep apnea are primarily caused by the loss of muscle tone in the upper airway during sleep.

Task channel respiratory instability

(1)evidences

Upper airway patency fails during sleep due to insufficient neural drive and potassium channel-mediated muscle relaxation.

Multi-pathway receptor signaling failure

(6)evidences

Loss of muscle tone during sleep leads to pharyngeal obstruction and subsequent respiratory arrest in apnea patients.